Analysts Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) PT at $17.75

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has earned an average rating of “Moderate Buy” from the seven analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $17.75.

ATRA has been the topic of several research reports. HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a report on Tuesday, January 28th. TD Cowen raised Atara Biotherapeutics to a “strong-buy” rating in a research report on Friday, November 29th. RODMAN&RENSHAW cut Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 21st. Canaccord Genuity Group reissued a “buy” rating and set a $17.00 price objective on shares of Atara Biotherapeutics in a report on Tuesday, March 11th. Finally, Rodman & Renshaw started coverage on Atara Biotherapeutics in a research note on Friday, December 20th. They issued a “buy” rating and a $25.00 target price for the company.

Atara Biotherapeutics Price Performance

ATRA opened at $6.92 on Friday. The company has a market capitalization of $40.54 million, a PE ratio of -0.27 and a beta of 0.49. Atara Biotherapeutics has a fifty-two week low of $5.40 and a fifty-two week high of $20.81. The business has a 50-day moving average of $7.74 and a 200-day moving average of $9.67.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Friday, March 7th. The biotechnology company reported ($1.19) EPS for the quarter, topping the consensus estimate of ($3.82) by $2.63. The business had revenue of $32.75 million for the quarter, compared to analyst estimates of $20.58 million. On average, equities research analysts expect that Atara Biotherapeutics will post -10.39 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Atara Biotherapeutics

Several hedge funds have recently made changes to their positions in ATRA. Geode Capital Management LLC raised its stake in shares of Atara Biotherapeutics by 9.5% during the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 4,043 shares in the last quarter. State Street Corp raised its position in Atara Biotherapeutics by 52.3% during the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after acquiring an additional 7,680 shares in the last quarter. FMR LLC lifted its stake in Atara Biotherapeutics by 41.7% in the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 7,381 shares during the last quarter. Staley Capital Advisers Inc. grew its position in shares of Atara Biotherapeutics by 25.0% in the 4th quarter. Staley Capital Advisers Inc. now owns 50,000 shares of the biotechnology company’s stock valued at $666,000 after acquiring an additional 10,000 shares during the period. Finally, Vestal Point Capital LP increased its stake in shares of Atara Biotherapeutics by 11.3% during the 3rd quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock worth $1,014,000 after purchasing an additional 12,677 shares during the last quarter. 70.90% of the stock is owned by institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.